

PRACTICAL APPLICATIONS OF New Agents IN ONCOLOGY™

GENERAL INFORMATION

The Cancer Therapy & Research Center (CTRC) Institute for Drug Development at the University of Texas Health Science Center at San Antonio (UT Health Science Center) invites you to the 15th Annual Practical Applications of New Agents in Oncology. The Friday sessions will be held at the Cancer Therapy & Research Center, 7979 Wurzbach Road, San Antonio, TX in the Mabee Conference Room, 4th Floor Grossman Building and the Saturday sessions will be held at the adjacent Greehey Children's Cancer Research Institute, 8403 Floyd Curl Drive, San Antonio. The conference begins Friday, February 7 and features an expanded nursing session with content of interest to all professionals and continues on Saturday, February 8. Don't miss the Friday evening reception where you can network with colleagues, invited speakers, and industry representatives. The reception will be held at 6:30pm at CTRC, 7979 Wurzbach Road, San Antonio, TX in the Mabee Conference Room, 4th Floor Grossman Building.

OVERVIEW

Cancer remains a leading cause of death in the country. Educating the healthcare professional about newly available agents in oncology is crucial.

The CTRC at The UT Health Science Center has hosted this event since 1998. As a National Cancer Institute-designated cancer center, one of the only four in the state of Texas, the CTRC is recognized for scientific excellence and extensive resources focused on cancer. CTRC's total patient care system – that consists of a breakthrough research, state-of-the-art technology, multidisciplinary clinical care delivered through a team of world-class physicians, laboratory scientists and other medical professionals – allows it to seamlessly translate the latest research directly to patients.

As a result of attending the conference, attendees will be able to cite the results of clinical studies of new anticancer agents and current dilemmas, with a principal focus on discerning the role of eventual role of new therapies in the clinical practice of oncology. They will also be able to describe the procedure for determining incorporation of new anticancer agents and therapeutics into clinical practice.

PROGRAM GOALS

To provide the most up-to-date treatment and care to patients with cancer; information regarding new agents must be spread to the healthcare professional community. The Practical Applications New Agents in Oncology conference disseminates this information to the healthcare professional who in turn will use it to provide the highest quality cancer treatment.

This conference will focus on the large number of new anticancer agents and related supportive therapeutics that have been approved over the last several years, as well as those that will likely be approved. Several world renowned and local speakers will discuss the incorporation of these agents into standard clinical practice, providing guidance to front-line clinicians, nurses and pharmacists regarding current or projected appropriate use of these therapeutics. Topics will include both early and late stages of various malignancies, and combined modality therapies (chemotherapy + surgery + radiotherapy) whenever pertinent.

EDUCATIONAL OBJECTIVES

As a result of participating in this continuing medical education activity, healthcare professionals will be able to:

- Cite the results of clinical studies of new anticancer agents and current dilemmas, with a principal focus on discerning the role or eventual role of new therapies in the clinical practice of oncology.
- Describe the procedure for determining the incorporation of new anticancer agents and therapeutics into clinical practice.
- Discuss the management of adverse effects associated with cancer treatment.
- Choose the appropriate treatment options for patients with cancer based on clinical data and individual patient characteristics.
- Discuss the novel agents in development for the treatment of cancer.

WHO SHOULD ATTEND?

The conference has an attractive case-based format and represents national points of view, making it a stimulating meeting for primary care and oncology clinicians, physicians, nurses, nurse practitioners, physician assistants, other health professionals, and medical students. Continuing Education credits will be provided for Medical, Nursing and Pharmacy.

DATE

February 7-8, 2014

HOTEL INFORMATION

Omni San Antonio Hotel at the Colonnade
9821 Colonnade Boulevard San Antonio, TX 78230
210-691-8888

<http://www.omnihotels.com/FindAHotel/SanAntonio.aspx>

Room Rate:

\$106 (plus tax) per night.

Please make your reservations directly with the hotel. Be sure to ask for the CTRC IDD Room Block to qualify for the special rate. These rooms will be held for conference attendees until Friday, January 17, 2014. After that date, the availability of rooms and conference rates cannot be guaranteed.

ACCREDITATION

Continuing Medical Education

The UT Health Science Center School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The UT Health Science Center School of Medicine designates this live educational activity for a maximum of *12.0 AMA PRA Category 1 Credits™*. Physicians should only claim credit commensurate with the extent of their participation in the activity.

COURSE DIRECTOR

Steven Weitman, M.D., Ph.D.

Director Institute for Drug Development

COURSE CO-DIRECTORS

Gerardo Medina, RN, CCRP

Director Research Nursing
Institute for Drug Development

Kim Wright

Project Coordinator
CTRC at the UT Health Science

Rachel Ortiz-Wong

Project Coordinator
CTRC at the UT Health Science

PLANNING COMMITTEE

Michelle Davis

Director, Clinical Trials Office
Institute for Drug Development

Anand Karnad, M.D.

Professor
Hematology/Oncology
CTRC at the UT Health Science
Center

Kevin Kelly, M.D.

Assistant Professor
Hematology/Oncology
CTRC at the UT Health Science
Center

Steffan Nawrocki, Ph.D.

Co-Director, Preclinical
Research, Institute for Drug
Development

Anita Lammers, Pharm.D.

Director, Pharmacy Operations
Investigational Drug Section,
CTRC at the UT Health Science
Center

Emily Koudelka

Manager, Business
Development
CTRC at the UT Health Science
Center

**Laura Alvarado, RN, MSN,
NEA-BC**

Director
Continuing Nursing Education
UT Health Science Center at
San Antonio School of Nursing

GUEST FACULTY

Harold J. Burstein, M.D., Ph.D.

Associate Professor of Medicine,
Dana-Farber Cancer Institute
Boston, MA

Saad A. Khan, M.D.

Assistant Professor Division of
Hematology and Oncology, UT
Southwestern Medical Center
Dallas, TX

Alan F. List, M.D.

President and CEO
Moffitt Cancer Center
Tampa, FL

**Rowena Schwartz, Pharm.D.,
BCOP**

Sr. Director, Clinical Content &
Services
McKesson Specialty Health
The Woodlands, TX

**Ian F. Tannock, M.D., Ph.D.,
DSc.**

Professor of Medical Oncology,
Princess Margaret Cancer
Centre
Toronto, Canada

LOCAL FACULTY

G. Richard Holt, M.D., D BE.

Bioethics Professor Emeritus
Otolaryngology
UT Health Science Center

Deva Mahalingam, M.D., Ph.D.

Assistant Professor
Hematology/Oncology
CTRC at the UT Health Science
Center

Laeq A. Malik, M.D.

Fellow, Institute for Drug
Development
Hematology/Oncology
CTRC at the UT Health Science
Center

Alex V. Mejia, M.D.

Fellow, Institute for Drug
Development
Hematology/Oncology
CTRC at the UT Health Science
Center

**Amelie G. Ramirez, M.P.H.,
Dr.P.H.**

Professor of Epidemiology &
Biostatistics
Director, Institute for Health
Promotion Research
UT Health Science Center

John Sarantopoulos, M.D.

Assistant Professor
Hematology/Oncology
CTRC at the UT Health Science
Center

Robert S. Svatek, M.D.

Assistant Professor
Division of Urology
UT Health Science Center

Jodi L. Taraba, Pharm.D., MSc.

Supervisor, IDS Pharmacy
CTRC at the UT Health Science
Center

Steven Weitman, M.D., Ph.D.

Professor and Director, Institute
for Drug Development
CTRC at the UT Health Science
Center

PRACTICAL APPLICATIONS OF
New Agents
IN ONCOLOGY™

Agenda

Friday, February 7, 2014

12:30-3:00pm Registration/Visit Exhibits

Moderator: Gerardo Medina, RN, OCN, CCRP

1:00-1:50pm Health Disparities
*Amelie G. Ramirez, M.P.H.,
Dr.P.H.*

1:50-2:00pm Q&A

2:10-3:00pm Ethical Conduct of Clinical
Research in Medical and
Surgical Oncology
Richard Holt, MD, D BE.

3:00-3:10pm Q&A

3:20-4:10pm Repurposing of Drugs for Use in
Oncology
Jodi L. Taraba., Pharm.D., MSc.

4:10-4:20pm Q&A

4:25-5:15pm Medication Management:
Opportunities to Optimize Care
with Oral/Self-Administered
Medications in Oncology
*Rowena Schwartz, Pharm.D.,
BCOP*

5:15-5:25pm Q&A

6:30 – 8:00pm Meet the Professor Reception

Saturday, February 8, 2014

7:00-8:00am Registration/Breakfast/Visit
Exhibits

Moderator: John Sarantopoulos, MD

8:00-8:05am Welcome
Steve Weitman, M.D., Ph.D.

8:05-8:55am New Treatments for MDS
Alan List M.D.

8:55-9:05am Q&A

9:10-9:45am Hematologic Cancers-What is
New?

Alex Mejia, M.D.

9:45-9:55am Q&A

10:00-10:50am Advances in Breast Cancer
Therapies
Harold Burstein, M.D., Ph.D.

10:50-11:00am Q&A

11:00-11:15am Break

11:15-11:50am New Treatments for Colorectal
Cancer
Laeq Malik, M.D.

11:50-12:00am Q&A

12:00-12:35pm New Approaches to Liver
Cancer

Deva Mahalingam, M.D., Ph.D.

12:35-12:45pm Q&A

12:45–1:45pm Lunch/Visit Exhibits

Moderator: Anand Karnad, M.D.

1:45-2:35pm Exciting News for Prostate
Cancer
Ian Tannock, M.D., Ph.D.

2:35-2:45pm Q&A

2:45-3:20pm Renal Cell Carcinoma
John Sarantopoulos, M.D.

3:20-3:30pm Q&A

3:30-3:45pm Break/Visit Exhibits

3:45-4:20pm Novel Therapeutic Approaches
to Manage Bladder Cancer
Robert Svatek, M.D.

4:20-4:30pm Q&A

4:30-5:05pm A New Era in Thyroid/Head and
Neck Cancer
Saad Khan, M.D.

5:05-5:15pm Q&A

5:30pm Adjourn